Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IH-2022 consolidation therapy
- Development stage
- Unknown
- Lead developer
- Institute of Hematology and Blood Diseases Hospital
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Oral, Intrathecal
01
Overview
IH-2022 consolidation therapy is a multi-agent chemotherapy regimen developed by the Institute of Hematology & Blood Diseases Hospital, China, for the treatment of adult patients with Philadelphia chromosome-negative (Ph-negative) acute lymphoblastic leukemia (ALL). This regimen is part of a pediatric-inspired protocol (IH-2022) and consists of a combination of vincristine, daunorubicin, cyclophosphamide, pegaspargase, prednisone, dexamethasone, cytarabine, 6-mercaptopurine, and high-dose methotrexate. It is typically administered following induction therapy to eliminate residual leukemia cells and reduce the risk of relapse. In current clinical trials, this consolidation phase is often evaluated in combination with targeted agents like venetoclax and immunotherapies such as blinatumomab to improve minimal residual disease (MRD) negativity and event-free survival.
- Other names
- Consolidation therapy (IH-2022)Pediatric-inspired consolidation chemotherapy
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)DHFR (Dihydrofolate reductase)GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on IH-2022 consolidation therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IH-2022 consolidation therapy.